Product Ordering Information Product Information XGEVA

Home , McKesson Corporation

Subcutaneous injection. Product Ordering Information Indication XGEVA™ is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. XGEVA™ is not indicated for the prevention of skeletal-related events in patients with multiple myeloma. Product Information

NDC Description Quantity 55513-730-01 120 mg/1.7 mL single-use vial One per carton Minimum Ordering Quantity — One dispensing carton Use a 27-gauge needle to withdraw and inject the entire contents of the vial. Syringe must be purchased separately. XGEVA™ Order Information Authorized Distributors: AmerisourceBergen Corporation Henry Schein, Inc. 1-800-829-3132 www.amerisourcebergen.com 1-800-772-4346 www.henryschein.com ASD Healthcare, Div. of AmerisourceBergen Specialty Group J.M. Blanco, Div. of AmerisourceBergen Corporation 1-800-837-5403 www.asdhealthcare.com 1-787-793-6262 Bellco Drug Corporation, Div. of AmerisourceBergen Corporation Kinray, Inc. 1-800-645-5314 www.bellcohealth.com 1-888-527-6806 www.kinray.com Besse Medical Supply, Div. of AmerisourceBergen Specialty Group McKesson Corporation 1-800-543-2111 www.besse.com 1-415-983-8300 www.mckesson.com Cardinal Health, Inc. McKesson Specialty Care Solutions 1-800-234-8701 www.cardinal.com Div. of McKesson Corporation 1-800-482-6700 Cardinal Health, Specialty Pharmaceutical Distribution 1-866-677-4844 www.cardinalhealth.com/spd Metro Medical Supply, Inc. 1-800-768-2002 www.metromedical.com CuraScript Specialty Distribution (Priority Healthcare Distribution) Morris & Dickson Company LLC 1-888-773-7376 www.curascript.com 1-800-388-3833 www.morrisdickson.com Dakota Drug, Inc. N.C. Mutual Wholesale Drug Company 1-800-437-2018 www.dakdrug.com 1-800-800-8551 www.mutualdrug.com Dik Drug Company Oncology Supply, Div. of AmerisourceBergen Specialty Group 1-630-655-4000 www.dikdrug.com 1-800-633-7555 www.oncologysupply.com DMS Pharmaceutical Group, Inc. Rochester Drug Corporation (RDC) 1-847-518-1100 www.dmspharma.com 1-800-333-0538 www.rdcdrug.com Florida Infusion Services, Inc. Smith Drug Company 1-800-624-0152 www.floridainfusion.com 1-864-582-1218 www.smithdrug.com Frank W. Kerr Company US Oncology Inc. 1-800-968-KERR www.fwkerr.com 1-832-601-8766 www.usoncology.com General Injectables & Vaccines, Div. of Henry Schein, Inc. Value Drug Company 1-800-521-7468 www.giv.com 1-800-252-3786 www.valuedrugco.com HD Smith Wholesale Drug Company 1-866-232-1222 www.hdsmith.com

Please see Important Safety Information on reverse. Subcutaneous injection.

Storage and Handling Requirements Supplied and Marketed by Store XGEVA™ in a refrigerator at 2°C to 8°C (36°F to 46°F) Amgen, Inc. in the original carton. Do not freeze. Once removed from the Internet www.Amgen.com refrigerator, XGEVA™ must not be exposed to temperatures above 25°C/77°F or direct light and must be used within Product Returns 14 days. Discard XGEVA™ if not used within the 14 days. Do For information and instructions regarding product not use XGEVA™ after the expiry date printed on the label. returns, please contact your wholesaler or Protect XGEVA™ from direct light and heat. Amgen Trade Operations at 1-800-28-AMGEN (1-800-282-6436). Credit for returns is subject to Avoid vigorous shaking of XGEVA™. Amgen’s current Returned Goods Policy. Shipping Container Information Product Information XGEVA™ should be unpacked and refrigerated. Medical Information: 1-800-77-AMGEN XGEVA™ should not be stored in the shipping (1-800-772-6436). container. Reimbursement Information Product Expiration TM The expiration date is printed on each dispensing Amgen Assist : 1-888-4ASSIST (1-888-427-7478) pack and vial label. or www.AmgenAssistOnline.com

Important Safety Information

• Hypocalcemia XGEVA™ can cause severe hypocalcemia. Correct pre-existing hypocalcemia prior to XGEVA™ treatment. Monitor calcium levels and administer calcium, magnesium, and vitamin D as necessary. Advise patients to contact a healthcare professional for symptoms of hypocalcemia.

• Osteonecrosis of the Jaw (ONJ) Osteonecrosis of the jaw (ONJ) can occur in patients receiving XGEVA™. Patients who are suspected of having or who develop ONJ while on XGEVA™ should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.

• Adverse Reactions The most common adverse reactions in patients receiving XGEVA™ were fatigue/asthenia, hypophosphatemia, and nausea. The most common serious adverse reaction in patients receiving XGEVA™ was dyspnea. The most common adverse reactions resulting in discontinuation of XGEVA™ were osteonecrosis and hypocalcemia.

Please see accompanying Prescribing Information.

1. Prescribing Information, XGEVATM.

Amgen One Amgen Center Drive Thousand Oaks, CA 91320-1799 www.amgen.com